Anticancer Drugs Oncology Pharmacology Physiotherapy Ramucirumab

Ramucirumab (24)

In this article, we will discuss Ramucirumab (24). So, let’s get started.

Clinical Trials Experience (4)

Ramucirumab Administered in Combination with Paclitaxel

Among 327 patients who received Ramucirumab (safety population) in Study 2, median age was 60 years, 31% were women, 63% were W Hite, and 33% were Asian. Patients in Study 2 received a median of 9 doses of Ramucirumab: the
median duration of exposure was 18 weeks, and 93 (28% of 327) patients received Ramucirumab for at least six months.
In Study 2, the most common adverse reactions (all grades) observed in patients treated with Ramucirumab plus paclitaxel at a rate of ≥30% and ≥2% higher than placebo plus paclitaxel were fatigue, neutropenia, diarrhea, and
epistaxis. The most common serious adverse events with Ramucirumab plus paclitaxel were neutropenia (3.7%) and febrile neutropenia (2.4%); 19% of patients treated with Ramucirumab plus paclitaxel received granulocyte colony-stimulating factors. Adverse reactions resulting in discontinuation of any component of the Ramucirumab plus paclitaxel combination in
2% or more patients in Study 2 were neutropenia (4%) and thrombocytopenia (3%).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.